Scholarlink

Background <p>As the latest drug available for the treatment of spinal muscular atrophy (SMA), real-world research data on risdiplam are still lacking. The purpose of this study was to supplement the real-world data in SMA children receiving risdiplam by studying children in multiple centers throughout China.</p> Results <p>In total, 34 children with SMA were collected from September 2021 to November 2024 and followed for a period of 8.3 ± 4.6 months. The Children’s Hospital of Philadelphia infant test of neuromuscular disorders (CHOPINTEND) scores of 18 children at the last visit improved when compared with baseline [20 (3–60) vs. 39 (8–61), <i>p</i> &lt; 0.001]. Thirteen patients (76.5%) demonstrated a noticeable improvement in Hammersmith functional motor scale expanded (HFMSE) score at the last follow-up compared with baseline [22 (6–52) vs. 31 (8–59), <i>p</i> = 0.003]. Revised upper limb module (RULM) scores of 7 patients at the last follow-up were improved compared with those at baseline [21 (6–32) vs. 24 (9–35), <i>p</i> = 0.018]. Improvements in motor function were monthly quantified by generalized estimating equation analysis. The CHOPINTEND score increased by 1.8 points/month (95%CI 0.8 to 2.9, <i>p</i> = 0.001) in children with short disease duration before treatment, 2.7 points/month (95%CI 2.4 to 3.0, <i>p</i> &lt; 0.001) in children with type 1 and 2.7 points/month (95%CI 2.1 to 3.3, <i>p</i> &lt; 0.001) in patients with 2 copies of survival motor neuron 2 gene. Pneumonia was the most frequently reported adverse event, whereas laboratory tests yielded no unusual findings.</p> Conclusion <p>Motor ability of children with SMA were improved under risdiplam with a good safety profile. The degree of motor function improvement was related to the course of disease before treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Longitudinal efficacy of risdiplam treatment in Chinese children with spinal muscular atrophy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Yue Yan,
  • Danhui Zhu,
  • Kai Ma,
  • Xufeng Luo,
  • Xiaoli Zhang,
  • Xiaolong Deng,
  • Mei Lu,
  • Yang Li,
  • Jianwei Li,
  • Feng Gao,
  • Shanshan Mao

摘要

Background

As the latest drug available for the treatment of spinal muscular atrophy (SMA), real-world research data on risdiplam are still lacking. The purpose of this study was to supplement the real-world data in SMA children receiving risdiplam by studying children in multiple centers throughout China.

Results

In total, 34 children with SMA were collected from September 2021 to November 2024 and followed for a period of 8.3 ± 4.6 months. The Children’s Hospital of Philadelphia infant test of neuromuscular disorders (CHOPINTEND) scores of 18 children at the last visit improved when compared with baseline [20 (3–60) vs. 39 (8–61), p < 0.001]. Thirteen patients (76.5%) demonstrated a noticeable improvement in Hammersmith functional motor scale expanded (HFMSE) score at the last follow-up compared with baseline [22 (6–52) vs. 31 (8–59), p = 0.003]. Revised upper limb module (RULM) scores of 7 patients at the last follow-up were improved compared with those at baseline [21 (6–32) vs. 24 (9–35), p = 0.018]. Improvements in motor function were monthly quantified by generalized estimating equation analysis. The CHOPINTEND score increased by 1.8 points/month (95%CI 0.8 to 2.9, p = 0.001) in children with short disease duration before treatment, 2.7 points/month (95%CI 2.4 to 3.0, p < 0.001) in children with type 1 and 2.7 points/month (95%CI 2.1 to 3.3, p < 0.001) in patients with 2 copies of survival motor neuron 2 gene. Pneumonia was the most frequently reported adverse event, whereas laboratory tests yielded no unusual findings.

Conclusion

Motor ability of children with SMA were improved under risdiplam with a good safety profile. The degree of motor function improvement was related to the course of disease before treatment.